Biohaven(NYSE) BHVN

Biohaven Ltd. makes medicines for people with brain and immune system disorders. It creates treatments for serious health issues like epilepsy and obesity. The company helps patients who need new options for chronic diseases.

Developing Next-Generation Medicines

• Epilepsy Treatments: Developing opakalim, an oral drug designed to stop seizures by targeting specific brain channels; currently in late-stage clinical trials.
• Protein Degraders: Creating molecules like BHV-1300 and BHV-1400 that remove harmful proteins from the body to treat immune diseases; works by sending proteins to the liver for disposal.
• Weight Management: Testing taldefgrobep alfa to help people with obesity lose fat while keeping muscle mass; acts by blocking a protein that limits muscle growth.
• Neurological Research: Advancing a portfolio of drugs focused on the nervous system and oncology to address unmet medical needs.

Strategic Moves and Partnerships

• Became an independent company in October 2022 following a spin-off from Biohaven Pharmaceutical Holding Company Ltd.
• Acquired a specialized ion-channel platform from Knopp in April 2022 to expand its neuroscience drug candidates.
• Reprioritized its research portfolio in the fourth quarter of 2025 to focus on three key programs with high value potential.
• Signed a deal with Regeneron Pharmaceuticals in July 2026 to study a cancer drug combination.
• Updated its agreement with Knopp in May 2024 to lower future royalty and milestone payments for certain drugs.

What Sets Biohaven Apart?

Biohaven uses its own technology platforms to create drugs that can selectively remove disease-causing proteins without hurting the rest of the immune system. The company focuses on drugs that patients can easily take themselves, such as through simple injections or pills.

A Look at the Finances

• Market capitalization grew to $2.2 billion in Q2 2026, up 55.2% year over year.
• Research and development expenses were $100.8 million for the three months ended June 30, 2026, a decrease of $83.6 million from the same period of 2025.
• Net loss for the three-month period ended June 30, 2026, was $137.3 million.
• Cash and marketable securities totaled $267.8 million as of June 30, 2026.
• Raised approximately $178.9 million in net proceeds through the sale of common shares during the six months ended June 30, 2026.

Evolution of the Business

Biohaven has transitioned from a subsidiary into an independent biopharmaceutical developer focused on late-stage clinical programs. Its shift toward cost-optimization and specific high-potential therapies highlights its focus on reaching commercial milestones.